Equities analysts expect that Kura Oncology, Inc. (NASDAQ:KURA) will announce ($0.37) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Kura Oncology’s earnings. The highest EPS estimate is ($0.29) and the lowest is ($0.49). Kura Oncology also posted earnings per share of ($0.37) in the same quarter last year. The company is expected to announce its next quarterly earnings results on Monday, November 6th.

According to Zacks, analysts expect that Kura Oncology will report full year earnings of ($1.54) per share for the current financial year, with EPS estimates ranging from ($1.82) to ($1.35). For the next fiscal year, analysts forecast that the firm will report earnings of ($1.91) per share, with EPS estimates ranging from ($2.70) to ($1.35). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research analysts that cover Kura Oncology.

Kura Oncology (NASDAQ:KURA) last posted its earnings results on Monday, August 7th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.03.

Several research firms have recently commented on KURA. Zacks Investment Research upgraded shares of Kura Oncology from a “sell” rating to a “hold” rating in a research note on Thursday, August 10th. Citigroup Inc. set a $13.00 target price on shares of Kura Oncology and gave the stock a “buy” rating in a research note on Tuesday, August 8th. Oppenheimer Holdings, Inc. restated a “buy” rating and issued a $16.00 target price on shares of Kura Oncology in a research note on Tuesday, July 4th. Leerink Swann restated an “outperform” rating and issued a $18.00 target price (up previously from $16.00) on shares of Kura Oncology in a research note on Thursday, August 10th. Finally, ValuEngine upgraded shares of Kura Oncology from a “sell” rating to a “hold” rating in a research note on Friday, September 8th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Kura Oncology presently has a consensus rating of “Buy” and a consensus target price of $16.00.

Several hedge funds have recently added to or reduced their stakes in KURA. State of Wisconsin Investment Board acquired a new stake in shares of Kura Oncology in the second quarter valued at about $102,000. Oppenheimer & Co. Inc. lifted its stake in shares of Kura Oncology by 14.7% in the first quarter. Oppenheimer & Co. Inc. now owns 12,500 shares of the company’s stock valued at $110,000 after purchasing an additional 1,600 shares during the period. Rhumbline Advisers acquired a new stake in shares of Kura Oncology in the second quarter valued at about $131,000. Nationwide Fund Advisors acquired a new stake in shares of Kura Oncology in the first quarter valued at about $136,000. Finally, New York State Common Retirement Fund acquired a new stake in shares of Kura Oncology in the second quarter valued at about $142,000. Institutional investors own 39.07% of the company’s stock.

Kura Oncology (NASDAQ:KURA) opened at 13.60 on Friday. The company’s 50-day moving average is $11.80 and its 200-day moving average is $9.58. The firm’s market capitalization is $271.84 million. Kura Oncology has a 52-week low of $4.00 and a 52-week high of $15.30.

WARNING: “Kura Oncology, Inc. (KURA) Expected to Announce Earnings of -$0.37 Per Share” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another website, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/10/15/kura-oncology-inc-kura-expected-to-announce-earnings-of-0-37-per-share.html.

About Kura Oncology

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

Get a free copy of the Zacks research report on Kura Oncology (KURA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kura Oncology (NASDAQ:KURA)

Receive News & Stock Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related stocks with our FREE daily email newsletter.